Evaluation of IGF1/IGFBP3 Molar Ratio as an Effective Tool for Assessing the Safety of Growth Hormone Therapy in Small-for-gestational-age, Growth Hormone-Deficient and Prader-Willi Children
Objective:IGF1 concentration is the most widely used parameter for the monitoring and therapeutic adaptation of recombinant human growth hormone (rGH) treatment. However, more than half the variation of the therapeutic response is accounted for by variability in the serum concentrations of IGF1 and...
Saved in:
Main Authors: | Meriem Gaddas (Author), Laurence Périn (Author), Yves Le Bouc (Author) |
---|---|
Format: | Book |
Published: |
Galenos Yayincilik,
2019-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Growth hormone therapy for Prader–Willi syndrome: challenges and solutions
by: Grugni G, et al.
Published: (2016) -
Clinical Characteristics and Growth Hormone Treatment in Patients with Prader-Willi Syndrome
by: Aydilek Dağdeviren Çakır, et al.
Published: (2021) -
The influence of genotype makeup on the effectiveness of growth hormone therapy in children with Prader-Willi syndrome
by: Qiong Zhou, et al.
Published: (2024) -
Growth hormone treatment in Prader-Willi syndrome patients: systematic review and meta-analysis
by: Caroline de Gouveia Buff Passone, et al.
Published: (2020) -
Effects of growth hormone-replacement therapy in patients with Prader-Willi syndrome - review of recent clinical trials
by: Michał Piwoński, et al.
Published: (2020)